Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Carfilzomib + Ricolinostat |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Carfilzomib | Kyprolis | PR-171 | Kyprolis (carfilzomib) binds to the 20S proteasome and inhibits its protein degradation activity, thereby leading to the accumulation of ubiquinated proteins, which may result in apoptosis and growth arrest in tumor cells (PMID: 26893241). Kyprolis (carfilzomib) in combination with lenalidomide and dexamethasone, or in combination with Darzalex Faspro (Daratumumab and hyaluronidase-fihj) and dexamethasone is FDA-approved for use in patients with multiple myeloma (FDA.gov). | |
Ricolinostat | ACY-1215 | HDAC Inhibitor 45 | Ricolinostat (ACY-1215) is a selective inhibitor of HDAC6, which may decrease tumor cell viability and reduce tumor growth, alone or in combination with other agents (PMID: 22262760, PMID: 27926524, PMID: 32705192). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|